Sinopharm proposes re-election of Lian Wanyong, Yang Binghua as executive directors

• Sinopharm flagged a board refresh, proposing to re-elect all current directors for a new three-year term starting Sept. 15.
• Executive slate includes President Lian Wanyong, former head of Shanghai Shyndec, previously held investment and policy roles at CNPGC.
• Also nominated: Yang Binghua, ex-SASAC official, former China TCM non-executive director, former Chongqing Taiji director.
• Chairman nominee Jin Bin previously ran CNPGC’s office, became CNPGC deputy general manager in 2022, later chief compliance officer.
• Extraordinary general meeting set for Sept. 15 to vote on the proposed re-elections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260824-12295398), on August 23, 2026, and is solely responsible for the information contained therein.